Bob Brown (Tasmania, Australian Greens) Share this | Hansard source

I could not agree more, but there is the other side to that coin—that is, the push for new drugs to be brought onto the PBS, which are not subject to the stringencies of the reference pricing system, that will not have the value for the people who purchase those drugs above and beyond drugs already existing on the market. We need to protect that system. I want to go back to the access to medicines working group, which we have been able to get information about from Senator Mason this morning. Could Senator Mason tell me what the Medicines Working Group is and the difference between the two?